Inhibition of fatty acid synthase with <scp>FT‐4101</scp> safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
Carine Beysen, Patricia Schroeder, Eric Wu, Julie Brevard, Maria Ribadeneira, Wei Lu, Kiran Dole, Terry O’Reilly, Linda Morrow, Marcus Hompesch, Marc Hellerstein, Kelvin W. Li, L. E. B. Johansson, Patrick Kelly (2020). Inhibition of fatty acid synthase with <scp>FT‐4101</scp> safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials. , 23(3), DOI: https://doi.org/10.1111/dom.14272.
